Upstream Bio, Inc. (UPB) Financial Analysis & Valuation | Quarter Chart
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapie... more
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory dis... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $247.61M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | E. Rand Sutherland |
| IPO Date | 2024-10-11 | CAGR | 33.04% |
| Employees | 75 | Website | upstreambio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
UPB chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $169.08M | P/E | -1.56 | Forward P/E | -1.65 | PEG | — |
| P/S | 0.16 | P/B | 0.01 | P/CF | -0.01 | P/FCF | -0.01 |
| Sales | $3.16M | Sales 1Y | 15.98% | Sales 3Y | — | Sales 5Y | — |
| EPS | $-2.91 | EPS 1Y | 40.1% | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | -25.24% | EPS QoQ | -2.67% | Sales QoQ Avg | 0.06% | EPS QoQ Avg | 0.7% |
| Gross Margin | 73.97% | Operating Margin | -5382.65% | Profit Margin | -4955.67% | ROCE | -62.68% |
| ROA | -56% | ROE | -48% | Altman Z Score | 13.37 | Piotroski Score | 2 |
| Current Ratio | 27.99 | Quick Ratio | 27.99 | Cash Ratio | 7.95 | Op. CF Ratio | -3.57 |
| Debt/Equity | 0 | Debt/Assets | 0 | Lt Debt/Equity | 0 | Lt Debt/Cap. | 0 |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.01 | Receivables Turnover | 4.09 |
| Enterprise Value | $169.08M | P/E Ratio | -1.56 |
| Forward P/E | -1.65 | PEG Ratio | — |
| P/S Ratio | 0.16 | P/B Ratio | 0.01 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $-2.91 | EPS Growth 1Y | 40.1% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 15.98% | Gross Margin | 73.97% |
| Operating Margin | -5382.65% | Profit Margin | -4955.67% |
| ROE | -48% | ROA | -56% |
| ROCE | -62.68% | Current Ratio | 27.99 |
| Quick Ratio | 27.99 | Cash Ratio | 7.95 |
| Debt/Equity | 0 | Interest Coverage | — |
| Altman Z Score | 13.37 | Piotroski Score | 2 |
Upstream Bio, Inc. (UPB) valuation & financials
Upstream Bio, Inc. (UPB) has a market capitalization of $247.61M and trades at a price-to-earnings ratio of -1.6. It operates in the Healthcare sector (Biotechnology).
Upstream Bio, Inc.'s revenue grew +16.0% over the last year.
Upstream Bio, Inc.'s next earnings report is scheduled for November 4, 2026 (provider scheduled date); analysts estimate EPS of $-0.73. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)